A recent study led by researchers from Integrated Diagnostics sheds light on the clinical utility of the company’s proteomic Xpresys Lung cancer test for evaluating indeterminate pulmonary nodules.
Published online in the journal Lung in September, the study found that with use of the test, 32 percent of surgeries and 32 percent of invasive procedures (surgeries plus biopsies) could be avoided. At the same time, the test was roughly equivalent to standard clinical practice in terms of the percentage of patients with malignant nodules it triaged to a regime of CT surveillance.
